Commense, Inc., an affiliate of PureTech Health plc developing microbiome-derived immune modulators for paediatric and maternal health, today announced the appointment of Edward J. Tad Stewart as President and Chief Executive Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Appointments_TadStewart_Commense_CEO.png400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-09 14:36:482018-04-09 14:36:48Commense Appoints Edward J. Stewart as President and CEO
https://european-biotechnology.com/wp-content/uploads/2024/04/DKFZ_Altzheimer.jpg517743Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-09 08:01:342018-04-09 08:01:34Blood test predincting Alzheimer’s paves way to earlier therapy
Human drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by three medical centres. They call to establish documentation standards for IBs/preclinical dossiers.
Nordic Nanovector ASA announces that Luigi Costa will step down as Chief Executive Officer by mutual agreement with the Board of Directors. A search for a new CEO will begin immediately. To ensure a smooth transition, Mr Costa has agreed to be available to the board until the end of July 2018.
https://european-biotechnology.com/wp-content/uploads/2024/04/app_Luigi_Costa.jpg245245h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-05 13:32:422018-04-05 13:32:42Nordic Nanovector’s Luigi Costa to step down as CEO
French Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio with a tumour microenvironment modifier that reactivates effector T cell responses.
Smith & Nephew plc today announced the appointment of Namal Nawana as Chief Executive Officer. He will join the Company and be appointed to the Board as an Executive Director on 7 May 2018.
https://european-biotechnology.com/wp-content/uploads/2024/04/2018_appointments_namalnawana.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-04 14:29:332018-04-04 14:29:33Namal Nawana appointed CEO of Smith & Nephew
Rutger Oudejans, Brand Director at bioLIVE, postulates that the bio supply chain could learn some lessons from the small molecules sector. The bio industry continues to expand at rates above the traditional NCE (New Chemical Entity) sector, yet for the supply chain there are vital synergies that could help further accelerate developments.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_spring_2018_Rutger_Oudejans.jpg5621000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-04 00:00:002024-04-02 16:21:25Learning from the small molecule supply chain
French allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellectis-CAR_T.jpg8001200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-03 18:44:152018-04-03 18:44:15Cellectis in offering of US$175m ADS following asset swap
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/csm_carsten-thiel_f88a4077c6.jpg282282h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-03 11:00:512018-04-03 11:00:51Abeona Therapeutics Appoints Carsten Thiel as CEO
Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients.
https://european-biotechnology.com/wp-content/uploads/2024/04/Ebi_3fra_deposited_chain_front_image-800x800.png800800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-03 08:26:332018-04-03 08:26:33Motif Bio to submit NDA for iclaprim
Commense Appoints Edward J. Stewart as President and CEO
AppointmentsCommense, Inc., an affiliate of PureTech Health plc developing microbiome-derived immune modulators for paediatric and maternal health, today announced the appointment of Edward J. Tad Stewart as President and Chief Executive Officer.
Blood test predincting Alzheimer’s paves way to earlier therapy
Latest NewsA newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis.
Poor investigator brochures: Resarchers call for standardisation
Latest NewsHuman drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by three medical centres. They call to establish documentation standards for IBs/preclinical dossiers.
Nordic Nanovector’s Luigi Costa to step down as CEO
AppointmentsNordic Nanovector ASA announces that Luigi Costa will step down as Chief Executive Officer by mutual agreement with the Board of Directors. A search for a new CEO will begin immediately. To ensure a smooth transition, Mr Costa has agreed to be available to the board until the end of July 2018.
Ose and Boehringer ink €1.1bn deal in immunoncology
Latest NewsFrench Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio with a tumour microenvironment modifier that reactivates effector T cell responses.
Namal Nawana appointed CEO of Smith & Nephew
AppointmentsSmith & Nephew plc today announced the appointment of Namal Nawana as Chief Executive Officer. He will join the Company and be appointed to the Board as an Executive Director on 7 May 2018.
Learning from the small molecule supply chain
BackgroundRutger Oudejans, Brand Director at bioLIVE, postulates that the bio supply chain could learn some lessons from the small molecules sector. The bio industry continues to expand at rates above the traditional NCE (New Chemical Entity) sector, yet for the supply chain there are vital synergies that could help further accelerate developments.
Cellectis in offering of US$175m ADS following asset swap
Latest NewsFrench allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis.
Abeona Therapeutics Appoints Carsten Thiel as CEO
AppointmentsAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.
Motif Bio to submit NDA for iclaprim
Latest NewsMotif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients.